Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 428

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 428
---
 a receiver over a substantial portion of its assets. Kadimastem may terminate the agreement for any reason by providing a sixty days’ notice, and Hadasit may terminate the agreement if regulatory approvals for the Clinical Trial are revoked. Upon termination, Kadimastem will pay Hadasit for work performed and any non -cancelablecommitments incurred up to the termination date, and Hadasit must return any unexpended funds. Termination does not affect Kadimastem’s intellectual property rights. As of the date of this proxy statement/prospectus, $2,113,661 have been paid by Kadimastem to Hadasit under this agreement. 218

Agreement with Pluri Inc. On July17, 2024, Kadimastem entered into a collaboration agreement with Pluri Inc. (Nasdaq: PLUR), or Pluri, for the clinical manufacturing (outsourced) of Kadimastem’s products, or the Pluri Agreement, at Pluri’s manufacturing facility in accordance with Kadimastem’s strategic plan. The signing of the Pluri Agreement to manufacture Kadimastem’s products constitutes a milestone in the development of the ASTRORX ®product, as part of Kadimastem’s preparation for a multi -sitePhase IIA clinical trial (Phase A2), as well as in the development of the ISLETRX product in support of the Pre -INDsubmission together with iTolerance, for continuing the development procedures of the innovative diabetes treatment within the framework of the aforementioned collaboration and as preparation for the submission of an IND application in the future. In accordance with the agreement, Kadimastem will grant Pluri the right to use the knowledge developed by Kadimastem for the benefit of Pluri’s production of Kadimastem’s products, with the first phase lasting up to 12months, in consideration of approximately $70,000 to be paid in cash or through issuance of Company securities, as to be agreed upon by the parties. The Pluri Agreement further provides that after completion of first phase, subsequent phases of work may be initiated only upon written agreement of both parties, subject to capacity availability at Pluri’s facilities. Pricing for subsequent phases will be negotiated separately and is valid for 12months from June30, 2024. Kadimastem is responsible for providing all process and assay data, starting materials, and raw materials unless otherwise agreed, and may be charged a 15% handling fee on raw materials proc